Axsome shares jump as settlement will keep Teva's Auvelity generic off the market until 2038
With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press release. Entrance of the generic will be delayed by an additional six months, until March 31, 2039, if Axsome gains an FDA pediatric exclusivity extension for its treatment.
Shares of Axsome Therapeutics ( AXSM 4.36%) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m. ET, but was ...
BofA analyst Jason Gerberry raised the firm’s price target on Axsome Therapeutics (AXSM) to $167 from $143 and keeps a Buy rating on the shares ...
Axsome Therapeutics, Inc. (NASDAQ:AXSM) signed a settlement agreement with Teva Pharmaceuticals Inc (NYSE:TEVA). The ...
UBS analysts increased the price target on Axsome Therapeutics (NASDAQ:AXSM) shares to $133.00, up from the previous $105.00, while maintaining a Buy rating on the stock. The company, currently valued ...
Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...
Shares of Axsome Therapeutics ( AXSM 20.22%) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m. ET, ...
Zacks Investment Research on MSN11h
Axsome (AXSM) Surges 20.2%: Is This an Indication of Further Gains?Axsome Therapeutics (AXSM) shares soared 20.2% in the last trading session to close at $127.08. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...
Truist Securities maintained a positive stance on Axsome Therapeutics (NASDAQ:AXSM), reiterating a Buy rating and a $190.00 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback